Stock ABBV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AbbVie Inc.

Equities

ABBV

US00287Y1091

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-07 pm EDT 		5-day change 1st Jan Change
169.4 USD +0.50% Intraday chart for AbbVie Inc. +5.07% +9.32%
12:18am Top law firms in US opioid lawsuits to get hundreds of millions in fees RE
Jun. 07 AbbVie's tight grip on Humira market raises concerns about biosimilars RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top law firms in US opioid lawsuits to get hundreds of millions in fees
RE
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
AQ
AbbVie - SkinMedica Celebrates 25 Years of Empowering Radiant Skin
AQ
AbbVie's tight grip on Humira market raises concerns about biosimilars
RE
AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint
MT
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
RE
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
PR
AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha Expressing Platinum-Sensitive Ovarian Cancer
CI
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
PR
Global markets live: Inditex, Intel, TSMC, Dollar Tree, AbbVie...
Our Logo
AbbVie Says First Patient Treated in Phase 3 Trial Assessing Potential Blood Cancer Treatment
MT
The odds of rates getting cut in 2024 may be better than you think
Our Logo
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
PR
AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
CI
HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $185 From $161
MT
ANALYST RECOMMENDATIONS : Abbvie, Air Products, Applied Materials, KLA Corporation, UnitedHealth...
Our Logo
AbbVie Says Arthritis Treatment Rinvoq Now Available for Certain Pediatric Patients in US
MT
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
PR
AbbVie's RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
CI
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. News AbbVie Inc.